M&A / Deals Blackstone closes $6.3B fund for life sciences investing BioPharma DiveIt's the biggest life sciences private fund ever raised, coming in nearly 40% larger than its Blackstone predecessor vehicle.M&A / DealsRead full story pharminent March 30, 2026 (Last updated: March 31, 2026) BioPharma Dive It’s the biggest life sciences private fund ever raised, coming in nearly 40% larger than its Blackstone predecessor vehicle. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 ReadoutNext: S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD-Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
